echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Scientists have found new targets for treating lung metastasis in breast cancer

    Scientists have found new targets for treating lung metastasis in breast cancer

    • Last Update: 2021-01-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    cancer is the most common malignant tumor in women in the world, and it is also one of the most fatal malignant tumor types. Of the many types of tumors, including breast cancer, more than 90% of cancer patients die as a result of cancer cell metastasis. Lung is the most common breast cancer far-end metastasis target organs, but also the body gas exchange site, lung metastasis on tumor patients have a fatal threat. Lung metastasis is the leading cause of treatment failure and patient death in the three-negative breast cancer subtype, which is currently the least effective treatment.
    The research team of Hu Guohong of the Shanghai Institute of Nutrition and Health of the Chinese Academy of Sciences found that tissue protease C (CTSC) could be used as a therapeutic target for pulmonary metastatic breast cancer, and that AZD7986, a clinical stage II small molecule compound specifically inhibiting CTSC, could significantly inhibit breast cancer cell lung metastasis. The findings were published recently in Cancer Cells.Hu Guohong's team found a significant positive correlation between the expression level of CTC and breast cancer lung metastasis, revealing that CTC is a marker and functional molecule in breast cancer lung metastasis.
    , we tracked lung metastasis in a large number of breast cancer patients and found that breast cancer patients with higher levels of CTSC protein in their preoperative serum had a higher risk of lung metastasis after surgery. Hu Guohong told reporters, "The CTC factor in the patient's serum can be used to assess the metastasis risk of breast cancer patients, which is a potential clinical diagnostic indicator that can help screen out high-risk tumor patients and thus pay attention to postoperative treatment." "
    " is not an accidental discovery, it is our seven-year research results. Initially, we found that CTSC may be associated with pulmonary metastasis through proteomic screening, but later, we used animal models and combined with a large number of clinical patient samples to verify that CTSC plays a vital role in lung metastasis in breast cancer. Thealso revealed the important regulatory role of micro-environment on cancer cell metastasis.
    " tumor metastasis is an inefficient and lengthy process. Breast cancer cells from the breast to the lungs, often in the form of a single or a few tumor cells, these individual seed cells just arrived at the transfer target organ, there is no harmful health effect, but after they grow into a new metastatic lesions tumor, is a fatal threat to patients. Hu Guohong explains, "It depends not only on the 'seed' (tumor cells) themselves, but also on whether there is a 'soil' suitable for the growth of the 'seeds' - the micro-environment, i.e. the normal tissue composition outside the tumor cells in the corresponding tissue organs." Tumor cells spread to new tissue organs, facing different 'micro-environments', either change themselves to adapt to the environment, or actively change the environment to suit themselves. In
    , researchers demonstrated that CTSC promotes lung metastasis in breast cancer cells by inducing neutral granulocytes to form DNA mesh structures rich in granulase.
    "Our study found that CTSC protein is an important way to change the environment by spreading tumor cells. Through CTSC, tumor cells draw an immune cell called neutral granulocytes from the blood to the lungs and induce them to form a special cobweb-like web structure, creating a 'soil' conducive to the growth of tumor cells. Therefore, this discovery provides us with new ideas for treatment by interfering with the interoperability of 'seeds' and 'soil'. Baseda series of studies, we speculate that CTC inhibitors should have therapeutic effects on breast cancer metastasis. Hu Guohong said.
    researchers found that the application of AZD7986 to mice with in-place transplant models of spontaneous lung metastasis significantly inhibited lung metastasis in breast cancer. CTSC-specific inhibitor AZD7986, developed by AstraZenecon to treat non-cystic fibrosis bronchid dilation, has entered clinical phase II trials. "We have tested and confirmed the possibility of AZD7986 as an inhibitor in preclinical animal models to treat lung metastasis in breast cancer."
    "CTSC is a potential therapeutic target, and we also found that drugs that inhibit CTSC have good value for breast cancer metastasis. It is expected that this research will promote the diagnosis and treatment of metastasis breast cancer in the future. Hu Guohong said. (Source: He Jing, China Science Journal)
    related paper information
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.